Drug Search Results
More Filters [+]

CRB-601

Alternative Names: crb-601, crb601, crb 601
Latest Update: 2024-11-12
Latest Update Note: News Article

Product Description

CRB-601 is a potent and selective alphavb8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment. (Sourced from: https://www.corbuspharma.com/press-releases/detail/368/corbus-presents-first-preclinical-data-for-crb-601-at-the)

Mechanisms of Action: aVb8 Antagonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Corbus
Company Location: NORWOOD MA 02062
Company CEO: Yuval Cohen
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CRB-601

Countries in Clinic: United Kingdom, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CRB-601-01

P2

Not yet recruiting

Oncology Solid Tumor Unspecified

2026-11-01

Recent News Events